AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $115,112,525 | -14.0% | 4,651,011 | -1.6% | 0.00% | -25.0% |
Q2 2023 | $133,848,080 | +21.0% | 4,726,274 | -1.9% | 0.00% | +33.3% |
Q1 2023 | $110,648,214 | -17.4% | 4,817,075 | +1.0% | 0.00% | -25.0% |
Q4 2022 | $133,909,982 | -1.2% | 4,768,874 | -0.5% | 0.00% | -20.0% |
Q3 2022 | $135,503,000 | +26.3% | 4,791,542 | -1.0% | 0.01% | +66.7% |
Q2 2022 | $107,258,000 | -29.2% | 4,838,013 | -7.0% | 0.00% | -25.0% |
Q1 2022 | $151,430,000 | -14.8% | 5,201,940 | -3.8% | 0.00% | -20.0% |
Q4 2021 | $177,779,000 | -33.1% | 5,408,536 | -6.1% | 0.01% | -28.6% |
Q3 2021 | $265,691,000 | -19.3% | 5,757,127 | -3.6% | 0.01% | -22.2% |
Q2 2021 | $329,256,000 | +36.2% | 5,974,507 | +27.7% | 0.01% | +28.6% |
Q1 2021 | $241,669,000 | +24.4% | 4,679,900 | +4.3% | 0.01% | +16.7% |
Q4 2020 | $194,335,000 | +15.8% | 4,485,000 | -6.5% | 0.01% | 0.0% |
Q3 2020 | $167,829,000 | -37.3% | 4,795,138 | -4.2% | 0.01% | -45.5% |
Q2 2020 | $267,764,000 | +66.6% | 5,006,831 | +10.5% | 0.01% | +37.5% |
Q1 2020 | $160,709,000 | -13.6% | 4,529,580 | +16.3% | 0.01% | +14.3% |
Q4 2019 | $185,908,000 | +97.0% | 3,893,394 | +33.7% | 0.01% | +75.0% |
Q3 2019 | $94,375,000 | -56.6% | 2,912,783 | -33.2% | 0.00% | -55.6% |
Q2 2019 | $217,585,000 | -3.2% | 4,362,184 | +30.8% | 0.01% | -10.0% |
Q1 2019 | $224,869,000 | +46.7% | 3,334,365 | +0.3% | 0.01% | +25.0% |
Q4 2018 | $153,292,000 | -39.5% | 3,324,479 | +1.2% | 0.01% | -27.3% |
Q3 2018 | $253,404,000 | -7.4% | 3,285,842 | +1.2% | 0.01% | -15.4% |
Q2 2018 | $273,601,000 | +4.4% | 3,248,251 | +1.3% | 0.01% | 0.0% |
Q1 2018 | $262,192,000 | +63.1% | 3,206,053 | +14.0% | 0.01% | +62.5% |
Q4 2017 | $160,803,000 | -16.1% | 2,812,717 | -2.1% | 0.01% | -20.0% |
Q3 2017 | $191,682,000 | +39.3% | 2,871,626 | +7.3% | 0.01% | +42.9% |
Q2 2017 | $137,648,000 | +8.8% | 2,675,380 | +23.5% | 0.01% | 0.0% |
Q1 2017 | $126,556,000 | +11873.1% | 2,167,074 | +8463.5% | 0.01% | +600.0% |
Q4 2016 | $1,057,000 | -63.8% | 25,306 | -54.2% | 0.00% | -75.0% |
Q3 2016 | $2,920,000 | +101.7% | 55,279 | +60.0% | 0.00% | +100.0% |
Q2 2016 | $1,448,000 | +898.6% | 34,560 | +859.5% | 0.00% | – |
Q1 2016 | $145,000 | +195.9% | 3,602 | +373.3% | 0.00% | – |
Q4 2015 | $49,000 | +19.5% | 761 | +31.4% | 0.00% | – |
Q3 2015 | $41,000 | -45.3% | 579 | -14.1% | 0.00% | – |
Q2 2015 | $75,000 | -97.2% | 674 | -97.6% | 0.00% | -100.0% |
Q1 2015 | $2,661,000 | -14.3% | 28,215 | +1.8% | 0.00% | 0.0% |
Q4 2014 | $3,105,000 | +83.9% | 27,715 | +0.7% | 0.00% | +100.0% |
Q3 2014 | $1,688,000 | -41.5% | 27,515 | -56.3% | 0.00% | -50.0% |
Q2 2014 | $2,887,000 | +35987.5% | 63,009 | +32212.3% | 0.00% | – |
Q1 2014 | $8,000 | +100.0% | 195 | +27.5% | 0.00% | – |
Q4 2013 | $4,000 | 0.0% | 153 | 0.0% | 0.00% | – |
Q3 2013 | $4,000 | – | 153 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |